Search

Your search keyword '"Alhalabi, Omar"' showing total 18 results
Start Over Author "Alhalabi, Omar" Publisher american society of clinical oncology
18 results on '"Alhalabi, Omar"'

1. Outcomes with sacituzumab govitecan (SG) in patients (pts) with advanced urothelial carcinoma (aUC) and variant histologies (VH): Analysis of the UNITE study.

Author

Nizam, Amanda, Jindal, Tanya, Jiang, Cindy Y., Alhalabi, Omar, Davidsohn, Matthew P., Bakaloudi, Dimitra Rafailia, Talukder, Rafee, Nguyen, Charles B, Oh, Eugene, Taylor, Amy K, Bilen, Mehmet Asim, Basu, Arnab, Kilari, Deepak, Emamekhoo, Hamid, Gupta, Shilpa, Grivas, Petros, Bellmunt, Joaquim, Campbell, Matthew T, Alva, Ajjai Shivaram, and Koshkin, Vadim S

Published
2024
Full Text
View/download PDF

2. Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study.

Author

Jindal, Tanya, Jiang, Cindy Y., Alhalabi, Omar, Nguyen, Charles B, Nizam, Amanda, Basu, Arnab, Bilen, Mehmet Asim, Zakharia, Yousef, Milowsky, Matthew I., Brown, Jason R, Kilari, Deepak, Emamekhoo, Hamid, Hoimes, Christopher J., Khaki, Ali Raza, Gupta, Shilpa, Grivas, Petros, Bellmunt, Joaquim, Campbell, Matthew T, Alva, Ajjai Shivaram, and Koshkin, Vadim S

Published
2024
Full Text
View/download PDF

3. Impact of squamous histology on outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma: Analysis of the UNITE study.

Author

Jindal, Tanya, Alhalabi, Omar, Nguyen, Charles B, Bakaloudi, Dimitra Rafailia, Nizam, Amanda, Bilen, Mehmet Asim, Basu, Arnab, Zakharia, Yousef, Milowsky, Matthew I., Brown, Jason R, Kilari, Deepak, Shah, Sumit, Emamekhoo, Hamid, Grivas, Petros, Hoimes, Christopher J., Gupta, Shilpa, Bellmunt, Joaquim, Campbell, Matthew T, Alva, Ajjai Shivaram, and Koshkin, Vadim S

Published
2024
Full Text
View/download PDF

4. Clinical outcomes of frontline GemFLP in advanced urachal and non-urachal adenocarcinomas of the urinary tract: The MD Anderson Cancer Center (MDACC) experience.

Author

Moussa, Mohammad Jad, Chen, Adrienne H., Grana, Allison K., Gao, Jianjun, Shah, Amishi Yogesh, Corn, Paul Gettys, Tannir, Nizar M., Goswami, Sangeeta, Wang, Jianbo, Araujo, John C., Kamat, Ashish M., Navai, Neema, Pettaway, Curtis Alvin, Adibi, Mehrad, Czerniak, Bogdan, Guo, Charles C., Siefker-Radtke, Arlene O., Campbell, Matthew T, and Alhalabi, Omar

Published
2024
Full Text
View/download PDF

5. Sequencing of erdafitinib (erda) and enfortumab vedotin (EV) in patients (pts) with fibroblast growth factor receptor (FGFR2/3) altered (alt) advanced urothelial cancer (aUC): Analysis of UNITE database.

Author

Jiang, Cindy Y., Hwang, Hyunsoo, Jindal, Tanya, Qiao, Wei, Epstein, Ilana, Nguyen, Charles B, Gupta, Shilpa, Shah, Sumit, Bilen, Mehmet Asim, Milowsky, Matthew I., Hoimes, Christopher J., Kilari, Deepak, Zakharia, Yousef, Emamekhoo, Hamid, Grivas, Petros, Bellmunt, Joaquim, Alva, Ajjai Shivaram, Koshkin, Vadim S, Campbell, Matthew T, and Alhalabi, Omar

Published
2024
Full Text
View/download PDF

8. Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study.

Author

Nizam, Amanda, Jindal, Tanya, Jiang, Cindy Y., Alhalabi, Omar, Bakaloudi, Dimitra Rafailia, Talukder, Rafee, Davidsohn, Matthew P., Nguyen, Charles B, Oh, Eugene, Taylor, Amy K, Lemke, Emily, Kilari, Deepak, Hoimes, Christopher J., Emamekhoo, Hamid, Gupta, Shilpa, Bellmunt, Joaquim, Grivas, Petros, Campbell, Matthew T, Alva, Ajjai Shivaram, and Koshkin, Vadim S

Published
2024
Full Text
View/download PDF

12. Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.

Author

Jindal, Tanya, Zhang, Li, Jiang, Cindy, Kilari, Deepak, Alhalabi, Omar, Nizam, Amanda, Basu, Arnab, Bilen, Mehmet Asim, Zakharia, Yousef, Milowsky, Matthew I., Shah, Sumit, Hoimes, Christopher J., Davis, Nancy B., Gupta, Shilpa, Emamekhoo, Hamid, Grivas, Petros, Bellmunt, Joaquim, Campbell, Matthew T, Alva, Ajjai Shivaram, and Koshkin, Vadim S

Published
2023
Full Text
View/download PDF

13. Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study.

Author

Jindal, Tanya, Jiang, Cindy, Alhalabi, Omar, Bakaloudi, Dimitra Rafailia, Talukder, Rafee, Davidsohn, Matthew, Nizam, Amanda, Taylor, Amy K, Nguyen, Charles B, Kilari, Deepak, Pywell, Cameron, Davis, Nancy B., Emamekhoo, Hamid, Sonpavde, Guru P., Gupta, Shilpa, Bellmunt, Joaquim, Grivas, Petros, Campbell, Matthew T, Alva, Ajjai Shivaram, and Koshkin, Vadim S

Published
2023
Full Text
View/download PDF

16. Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC).

Author

Koshkin, Vadim S, Henderson, Nicholas, Kilari, Deepak, Jindal, Tanya, Alhalabi, Omar, Freeman, Dory, Basu, Arnab, Barata, Pedro C., Bilen, Mehmet Asim, Zakharia, Yousef, Emamekhoo, Hamid, Shah, Sumit, Milowsky, Matthew I., Davis, Nancy B., Gupta, Shilpa, Hoimes, Christopher J., Grivas, Petros, Bellmunt, Joaquim, Campbell, Matthew T, and Alva, Ajjai Shivaram

Published
2023
Full Text
View/download PDF

17. Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.

Author

Jindal, Tanya, Kilari, Deepak, Alhalabi, Omar, Nizam, Amanda, Khaki, Ali Raza, Basu, Arnab, Barata, Pedro C., Bilen, Mehmet Asim, Shah, Sumit, Zakharia, Yousef, Milowsky, Matthew I., Bellmunt, Joaquim, Emamekhoo, Hamid, Davis, Nancy B., Grivas, Petros, Gupta, Shilpa, Hoimes, Christopher J., Campbell, Matthew T, Alva, Ajjai Shivaram, and Koshkin, Vadim S

Published
2023
Full Text
View/download PDF

18. Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review.

Author

Crupi E, Costa de Padua T, Marandino L, Fallara G, Pederzoli F, Cimadamore A, Goetz EC, Cigliola A, Patané DA, Mercinelli C, Tateo V, Salonia A, Briganti A, Montorsi F, Meeks JJ, Spiess PE, Alhalabi O, Gao J, Kamat AM, Grivas P, Necchi A, and Raggi D

Subjects
Humans, Urinary Bladder Neoplasms pathology, Urinary Bladder Neoplasms metabolism, Male, Nectins, Urogenital Neoplasms pathology, Urogenital Neoplasms metabolism, Cell Adhesion Molecules analysis
Abstract

Purpose: Aberrant expression of nectin-4 (N4) has been observed in several malignancies emerging as new target for antibody-drug conjugates, especially in urothelial carcinoma of the bladder (UBC). Limited data on N4 positivity in nonurothelial genitourinary (GU) cancers are available. This systematic-review aimed to investigate N4 positivity among GU malignancies., Methods: A systematic literature review was performed on March 2023 using PubMed, MEDLINE, and Embase databases according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Protocol was amended to incorporate a new updated search on March 2024., Results: Twenty-five studies evaluating N4 positivity in GU tumors were included, 14 on UBC, three on upper tract urothelial carcinoma (UTUC), six on histologic subtypes (HS) and divergent histology of the bladder, one on papillary renal cell carcinoma (pRCC), one in chromophobe RCC (chRCC), two on penile cancer, one in prostate cancer (PCa). Among UBC, stratifying per stage N4 positivity was higher in metastatic (weighted mean [WM], 90.8; range, 59.6-100) and in non-muscle-invasive (WM, 87.4; range, 86.7-88.3) than in muscle-invasive UC (WM, 83.1; range, 68.2-100). The N4 positivity of UBC was higher than UTUC (WM, 62.9; range, 44.4-65.7). Immunohistochemistry N4 positivity was reported to be lower in non-UC malignancies, including pRCC (WM, 44.1; range, 44.1-44.1), HS (WM, 63.5; range, 0-100), PCa (WM0; range, 0-0), chRCC (WM, 18.5; range, 18.5-18.5), and penile cancer (WM, 86.5; range, 61.4-98.3), compared with UBC overall (WM, 87.1; range, 59.6-100)., Conclusion: Non-UC malignancies seem to have a lower N4 positivity rate than UC. N4 positivity in bladder cancer appears to vary according to stage and presence of HS. The predictive and prognostic role of N4 must be further characterized in larger and prospective studies.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results